文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

社区获得性大肠埃希菌与金黄色葡萄球菌血流感染的死亡率及住院时长:九個中低收入国家的观察性研究

Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries.
PubMed 文献 · Clin Infect Dis · 2026-01-01

ACORN2前瞻性临床监测研究纳入9个中低收入国家的成人和儿童,比较社区获得性耐药与敏感大肠埃希菌及金黄色葡萄球菌血流感染患者与血培养阴性对照的院内死亡和出院竞争风险。结果显示耐药感染未增加死亡率,但耐药血流感染住院时长较敏感感染延长,置信区间包含0天。

要点

  • 耐药大肠埃希菌和金黄色葡萄球菌血流感染的院内死亡率与敏感感染相比无显著差异。
  • 3GC-S大肠埃希菌血流感染患者 adjusted 死亡风险显著高于对照(HR 1.73)。
  • 耐药血流感染住院时长较敏感感染延长,但置信区间包含0天。

核心结论

  • 在ACORN2研究中,耐药感染与死亡率增加无关。
  • 耐药血流感染住院时长较敏感感染延长,但置信区间包含0天。

研究设计与样本

  • ACORN2为前瞻性临床监测研究,纳入9个中低收入国家的成人和儿童。
  • 将社区获得性敏感和耐药大肠埃希菌及金黄色葡萄球菌血流感染患者与血培养阴性对照组比较。
  • 计算院内死亡和出院存活的病因特异性风险比(HR)及住院时长。

主要发现

  • 院内死亡率:对照组8.4%,大肠埃希菌血流感染20.1%(3GC-R 20.3%,3GC-S 19.7%),金黄色葡萄球菌血流感染13.1%(MRSA 12.2%,MSSA 13.7%)。
  • 耐药与敏感大肠埃希菌和金黄色葡萄球菌血流感染患者出院存活风险较对照显著降低;耐药较敏感感染住院时长分别延长2天(95%CI 0-3)和1天(95%CI -1至3)。

临床怎么用

  • 中低收入国家社区获得性耐药大肠埃希菌和金黄色葡萄球菌血流感染未显示死亡率增加,但需关注住院时长延长。
  • 临床应继续监测耐药血流感染的死亡风险及医疗资源负担。

局限性

  • 耐药与敏感感染住院时长差异的置信区间包含0天,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance disproportionally affects low- and middle-income countries. We calculated the burden of resistant and susceptible Escherichia coli and Staphylococcus aureus bloodstream infections (BSIs) in ACORN2, a prospective clinical surveillance study in adults and children. METHODS: Patients with culture-confirmed community-acquired susceptible and resistant E. coli (third-generation cephalosporin susceptible [3GC-S] and resistant [3GC-R]) and S. aureus (methicillin-resistant [MRSA] and methicillin-susceptible [MSSA]) BSIs were compared against blood culture-negative patients (controls). Cause-specific hazard ratios (HRs) were calculated for competing events of in-hospital mortality and discharge alive. Length of hospital stay (LOS) was calculated. RESULTS: From 22 802 blood cultures taken, there were 329 E. coli (177 [53.8%] 3GC-R) and 363 S. aureus (132 [36.4%] MRSA) BSIs. In-hospital mortality was 8.4% for controls, 20.1% for E. coli (20.3% 3GC-R; 19.7% 3GC-S), and 13.1% for S. aureus (12.2% MRSA; 13.7% MSSA). 3GC-S but not 3GC-R E. coli BSI cases had higher adjusted hazard of death than controls (HRs, 1.73 [95% confidence interval {CI}, 1.20-2.49] and 1.38 [95% CI, .99-1.94]); risk of dying was the same for 3GC-S compared with 3GC-R infections (P = .882). Neither MSSA nor MRSA BSI patients were more likely to die than controls (HRs, 1.33 [95% CI, .91-1.93] and 1.00 [95% CI, .61-1.66]) nor MSSA versus MRSA (P = .891). The hazard of discharge alive for both resistant and susceptible S. aureus and E. coli decreased significantly when compared with controls. LOS was 2 (95% CI, 0-3) days and 1 (95% CI, -1 to 3) day longer for resistant compared with susceptible infections, for E. coli and S. aureus. CONCLUSIONS: Antimicrobial-resistant infections were not associated with increased mortality in ACORN2. Drug-resistant BSI had longer LOS compared with susceptible infections, but CIs encompassed 0 days.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hopkins J, Tosas-Auguet O, Waithira N, et al. Mortality and Length of Stay Associated With Community-Acquired Escherichia coli and Staphylococcus aureus Bloodstream Infections: An Observational Study in 9 Low- and Middle-Income Countries. Clin Infect Dis. 2026. PMID: 42227749. doi:10.1093/cid/ciag275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。